Search
FORGEN II VV5 Genomic Targeting of recombinant Adeno-Associated Virus
FORGEN II VV5 Genomic Targeting of recombinant Adeno-Associated Virus The adeno-associated virus (AAV) has promising features as a vector for somatic gene therapy, e.g. AAV displays a wide tropism,…
FORGEN II VV4 Foamy virus – derived vectors for somatic gene therapy
FORGEN II VV4 Foamy virus – derived vectors for somatic gene therapy
FORGEN II VV3 Identification of breastcancer –specific HERV promoters'
FORGEN II VV3 Identification of breastcancer –specific HERV promoters'
FORGEN II VV2 Generation of transgenic animals to evaluate the efficiency and safety of replication-competent, mammary tumor-specific ProCon vectors for gene therapy
FORGEN II VV2 Generation of transgenic animals to evaluate the efficiency and safety of replication-competent, mammary tumor-specific ProCon vectors for gene therapy Transgenic animals offer the…
FORGEN II VV1 Gentherapie mittels retroviraler Vektoren zur Behandlung von Brustkrebs
FORGEN II VV1 Gentherapie mittels retroviraler Vektoren zur Behandlung von Brustkrebs
FORGEN II IS8 Differences between strains of Listeria monocytogenes-detection and implications for adherence, invasion, tissue specificity, and environmental persistence
FORGEN II IS8 Differences between strains of Listeria monocytogenes-detection and implications for adherence, invasion, tissue specificity, and environmental persistence
FORGEN II IS7 Single stranded Olegonucleotide : Induction of antigen specific Th-1 versus Th-2 immune responses
FORGEN II IS7 Single stranded Olegonucleotide : Induction of antigen specific Th-1 versus Th-2 immune responses
FORGEN II IS6 Live Vaccines as a tumor vaccine for therapeutic and prophylactic tretment of cancer
FORGEN II IS6 Live Vaccines as a tumor vaccine for therapeutic and prophylactic tretment of cancer
FORGEN I LI4 Entwicklung und Evaluierung stammspezifischer Nukleinsäuresonden für bei der Entwicklung von sicheren Lebendimpfstoffen relevante Bakterien
FORGEN I LI4 Entwicklung und Evaluierung stammspezifischer Nukleinsäuresonden für bei der Entwicklung von sicheren Lebendimpfstoffen relevante Bakterien
FORGEN I LI3 Sicherheitsaspekte bei der Entwicklung rekombinanter Yersinia enterocolitica-Stämme als neue Lebendvakzine
FORGEN I LI3 Sicherheitsaspekte bei der Entwicklung rekombinanter Yersinia enterocolitica-Stämme als neue Lebendvakzine